Iron-Chelating Therapy
The DOI matches its Crossref record; 242 of the 242 references it cites were found in a registry or an index.
Abstract
Because of the catalytic action of iron in one-electron redox reactions, it has a key role in the formation of harmful oxygen derivatives and production of peroxidative damage to vital cellular structures. The clinical manifestations of iron overload may be prevented and even reversed by the effective administration of the iron-chelating drug deferoxamine (DF). Recent experimental evidence suggests that DF may also be useful in modifying disease conditions unrelated to iron overload by preventing the formation of free radicals, the powerful final effectors of tissue damage resulting from the respiratory burst of granulocytes and macrophages participating in the inflammatory response. Although much experimental work is still needed, this novel approach in iron-chelating therapy may have far-reaching implications in the management of autoimmune disease, adult respiratory distress syndrome, and organ transplantation. The poor intestinal absorption of DF, its almost prohibitive price, and short duration of action underline the need for new, orally effective iron chelators. A number of very promising orally effective drugs have been identified in recent years, such as the polyanionic amines, aryl hydrazones, and hydroxypyridones. Further development for clinical use of this new generation of iron-chelating drugs is a major challenge for future research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ascorbate can replace O2•- within the cell for reducing the Fe(III) to Fe(II) [68].”
Citations
Cites
Oxygen toxicity, oxygen radicals, transition metals and disease
Halliwell, B., & Gutteridge, J. M. C. (1984) · Biochemical Journal · doi:10.1042/bj2190001 · Cited by 5,330
Oxygen free radicals and iron in relation to biology and medicine: Some problems and concepts
Halliwell, B., & Gutteridge, J. M. C. (1986) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(86)90305-x · Cited by 2,038
Gutteridge, J. M. C., Richmond, R., & Halliwell, B. (1979) · Biochemical Journal · doi:10.1042/bj1840469 · Cited by 626
The Biochemistry of Desferrioxamine and its Relation to Iron Metabolism
Keberle, H. (1964) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb54077.x · Cited by 612
Medical Treatment of Osteoarthritis
(1965) · The Lancet · doi:10.1016/s0140-6736(65)91263-8 · Cited by 554
Buja, L. M., & Roberts, W. C. (1971) · The American Journal of Medicine · doi:10.1016/0002-9343(71)90240-3 · Cited by 472
Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions
Olivieri, N. F., Buncic, J. R., Chew, E., Gallant, T., Harrison, R. V., Keenan, N., Logan, W., Mitchell, D., Ricci, G., Skarf, B., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604033141402 · Cited by 429
Ribonucleotide Reductase—a Radical Enzyme
Reichard, P., & Ehrenberg, A. (1983) · Science · doi:10.1126/science.6306767 · Cited by 423
Non‐Specific Serum Iron in Thalassaemia: an Abnormal Serum Iron Fraction of Potential Toxicity
Hershko, C., Graham, G., Bates, G. W., & Rachmilewitz, E. A. (1978) · British Journal of Haematology · doi:10.1111/j.1365-2141.1978.tb03662.x · Cited by 423
Self-citationIn vivo damage of rat lungs by oxygen metabolites.
Johnson, K. J., Fantone, J. C., Kaplan, J., & Ward, P. A. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110149 · Cited by 359
Research works printed but not linked: 66
- Brown E. B., 1957, J. Lab. Clin. Med., 50, 862
- Awai M., 1979, Am. J. Pathol, 95, 663
- Editorial, 1985, Lancet, 1, 143
- Yamanoi Y., 1982, Acta Haematol. Jpn., 45, 1229
- Ganote C. E., 1973, Lab. Invest., 28, 426
- Iancu T. C., 1987, Br. J. Exp. Pathol., 68, 53
- Hershko C, 1977, Prog. Hemalol., 10, 105
- Jacobs A., 1978, Br. J. Exper. Pathol., 59, 489
- Link G., 1985, J. Lab. Clin. Med., 106, 147
- Yamanoi Y., 1984, Acta Med. Okayama, 38, 423
- Awai M., 1982, The Biochemistry and Physiology of Iron, 543
- Byers B. R., 1982, The Biochemistry and Physiology of Iron, 179
- Sciortino C. V., 1980, J. Lab. Clin. Med., 96, 1081
- Cox P. G., 1981, Am. J. Pathol., 102, 151
- Hershko C., 1987, J. Lab. Clin. Med., 110, 355
- Weatherall D. J., 1981, Thalassaemia Syndromes3rd ed
- Hoffbrand A. V, 1980, Iron in Biochemistry and Medicine II, 499
- Pippard M. J., 1977, Lancet, 2, 739
- Hershko C., 1973, J. Lab. Clin. Med., 81, 876
- Cumming R. L. C., 1967, Lancet, 1, 71
- Kim B. K., 1985, J. Lab. Clin. Med., 105, 440
- Hershko C, 1975, J. Lab. Clin. Med., 85, 913
- Hershko C., 1978, J. Lab. Clin. Med., 92, 144
- Wagstaff M., 1985, Br. J. Haematol., 61, 566
- Waxman H. S., 1969, Prog. Hematol., 6, 338
- Pippard M. J., 1978, Clin. Sci. Mol. Med., 54, 99
- Anon, 1984, Lancet, 1, 373
- 10.1161/01.CIR.30.5.698 · DOI · Paper page
- Flynn D. M., 1982, Birth Defects Orig. Art. Ser., 18, 347
- Henry W, 1979, Ann. Intern. Med., 91, 892
- Heys A. D., 1981, Clin. Sci., 60, 295, 10.1042/cs0600295 · DOI · Paper page
- Blake D. R., 1985, Q. J. Med., 56, 345
- Arden G. B, Desferrioxamine administered intravenously by infusion causes a loss of retinal sensitivity in rabbits anesthetised with urethane
- Gallant T., 1986, N. Engl. J. Med., 314, 1643
- Calescibetta C. C., 1986, Am. J. Kidney Dis., 8, A20
- Goodill J. J., 1987, N. Engl. J. Med., 317, 54
- Polson R. J., 1986, Q. J. Med., 61, 1153
- Fligiel S. E. G., 1984, Am. J. Pathol., 115, 375
- Weinberg K., 1986, Blood, 68, 286a
- Cross C. E., 1985, J. Lab. Clin. Med., 106, 433
- Fritch G., 1985, Exp. Pathol., 60, 171
- Ramsay C. A., 1974, Q. J. Med., 43, 1
- Praga M., 1987, N. Engl. J. Med., 316, 547
- Neilands J. B, 1981, Development of Iron Chelators for Clinical Use, 13
- Jacobs A, 1981, Development of Iron Chelators for Clinical Use, 39
- Grady R. W., 1981, Development of Iron Chelators for Clinical Use, 133
- Pitt C. G., 1979, J. Pharmacol. Exp. Ther., 208, 12
- Hershko C., 1984, J. Lab. Clin. Med., 103, 337
- Gyparaki M., Acta Haematol.
- Pitt C. G, 1981, Development of Iron Chelators for Clinical Use, 105
- Kontoghiorghes G. J, 1986, Mol. Pharmacol., 30, 670
- Grady R. W., 1978, J. Pharmacol. Exp. Ther., 205, 757
- Hershko C., 1978, J. Lab. Clin. Med., 92, 144
- Grady R. W., 1979, J. Pharmacol. Exp. Ther., 209, 342
- Winston A., 1985, J. Pharmacol. Exp. Ther., 232, 644
- Peterson C. M., 1979, Exp. Hematol., 7, 74
- Harris W. R., 1979, J.C.S. Chem. Commun., 177, 178
- Fahey J. L., 1961, J. Lab. Clin. Med., 57, 436
- Stifel F. B., 1967, J Anim. Sci., 26, 126
- Ponka P., 1970, FEBS Lett., 97, 317
- Hershko C., 1981, J. Lab. Clin. Med., 98, 99
- Johnson D. K., 1982, J. Pharmacol. Exp. Ther., 221, 399
- Brown E. B, 1981, Development of Iron Chelators for Clinical Use, 47
- Gyparaki M., 1987, Thalassemia Today. The Mediterranean Experience, 521
- Peter H. H, 1983, Schweiz. Med. Wschr., 113, 1428
- Pippard M. J., 1986, Scand. J. Haematol., 36, 466, 10.1111/j.1600-0609.1986.tb02282.x · DOI · Paper page
Cited by
Iron-Chelating Therapy and the Treatment of Thalassemia
Olivieri, N. F., & Brittenham, G. M. (1997) · Blood · doi:10.1182/blood.v89.3.739 · Cited by 1,089
Olivieri, N. F. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907083410207 · Cited by 728
Role of antioxidants in paraquat toxicity
Suntres, Z. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00382-7 · Cited by 711
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
Metadata
- Authors
- Hershko, C., Weatherall, D. J., & Finch, C.
- Affiliations
- Hebrew University of Jerusalem (IL)
- University of Oxford (GB)
- University of Washington (US)
- ORCID
- Hershko, Chaim
- Venue
- CRC Critical Reviews in Clinical Laboratory Sciences
- Publisher
- Informa UK Limited
- Published
- 1988-01
- Volume
- 26
- Issue
- 4
- Pages
- 303-345
- ISSN
- 0590-8191 (ISSN-L)
- OpenAlex
- W1997531635
- Cited by
- 141
- References
- 241
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2020: 2 · 2017: 4 · 2016: 2 · 2015: 2 · 2014: 1 · 2013: 2 · 2012: 1
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CRC Critical Reviews in Clinical Laboratory Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (3406-02)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
- Keywords
- iron chelation, deferoxamine, iron overload, free radicals, reactive oxygen species, oxidative stress, respiratory burst, granulocytes, macrophages, autoimmune disease, acute respiratory distress syndrome, organ transplantation, oral iron chelators, arylhydrazones, iron absorption
- MeSH terms
- Animals, Ascorbic Acid, Deferoxamine, Hemochromatosis, Humans, Iron, Iron Chelating Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Iron-Chelating Therapy. https://app.cochat.ai/papers/10.3109/10408368809105894
- The paper
- Hershko, C., Weatherall, D. J., & Finch, C. (1988). Iron-Chelating Therapy. CRC Critical Reviews in Clinical Laboratory Sciences. https://doi.org/10.3109/10408368809105894
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.